OTC Markets Group Welcomes Repro Med Systems to OTCQX

NEW YORK, Sept. 18, 2015

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

Repro Med begins trading today on OTCQX under the symbol "REPR."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are pleased to welcome Repro Med to the family of established, global and growth companies on our OTCQX market," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "OTCQX provides a transparent public trading market for growing companies like Repro Med that are committed to maintaining high-quality financial and operating standards.  We look forward to supporting Repro Med in its continued growth as a publicly-traded company."

Andrew Sealfon, President of Repro Med Systems, commented, "Our focus on building our core business is bearing gratifying results in building value for our shareholders.  Qualifying for trading on OTCQX is an important step in fulfilling our commitments to transparency and compliance.  It is also an important foundation for executing our long term strategy for product line expansion and profitable sales growth."

Salon Marrow Dyckman Newman & Broudy LLP serves as Repro Med's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

Repro Med designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications to be sold domestically and internationally.